537 related articles for article (PubMed ID: 17341507)
1. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Feitsma AL; Toes RE; Begovich AB; Chokkalingam AP; de Vries RR; Huizinga TW; van der Helm-van Mil AH
Rheumatology (Oxford); 2007 Jul; 46(7):1092-5. PubMed ID: 17341507
[TBL] [Abstract][Full Text] [Related]
2. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
[TBL] [Abstract][Full Text] [Related]
3. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
Kokkonen H; Johansson M; Innala L; Jidell E; Rantapää-Dahlqvist S
Arthritis Res Ther; 2007; 9(3):R56. PubMed ID: 17553139
[TBL] [Abstract][Full Text] [Related]
4. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease.
Johansson M; Arlestig L; Hallmans G; Rantapää-Dahlqvist S
Arthritis Res Ther; 2006; 8(1):R19. PubMed ID: 16507117
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.
Lundström E; Källberg H; Smolnikova M; Ding B; Rönnelid J; Alfredsson L; Klareskog L; Padyukov L
Arthritis Rheum; 2009 Apr; 60(4):924-30. PubMed ID: 19333936
[TBL] [Abstract][Full Text] [Related]
6. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
van Oene M; Wintle RF; Liu X; Yazdanpanah M; Gu X; Newman B; Kwan A; Johnson B; Owen J; Greer W; Mosher D; Maksymowych W; Keystone E; Rubin LA; Amos CI; Siminovitch KA
Arthritis Rheum; 2005 Jul; 52(7):1993-8. PubMed ID: 15986374
[TBL] [Abstract][Full Text] [Related]
7. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis.
Orozco G; Pascual-Salcedo D; López-Nevot MA; Cobo T; Cabezón A; Martín-Mola E; Balsa A; Martín J
Rheumatology (Oxford); 2008 Feb; 47(2):138-41. PubMed ID: 18156150
[TBL] [Abstract][Full Text] [Related]
8. The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population.
Wesoly J; Hu X; Thabet MM; Chang M; Uh H; Allaart CF; Toes RE; Houwing-Duistermaat JJ; Begovich AB; Huizinga TW
Rheumatology (Oxford); 2007 Apr; 46(4):617-21. PubMed ID: 17135225
[TBL] [Abstract][Full Text] [Related]
9. Associations between genetic factors, tobacco smoking and autoantibodies in familial and sporadic rheumatoid arthritis.
Michou L; Teixeira VH; Pierlot C; Lasbleiz S; Bardin T; Dieudé P; Prum B; Cornélis F; Petit-Teixeira E
Ann Rheum Dis; 2008 Apr; 67(4):466-70. PubMed ID: 17660221
[TBL] [Abstract][Full Text] [Related]
10. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.
van der Woude D; Rantapää-Dahlqvist S; Ioan-Facsinay A; Onnekink C; Schwarte CM; Verpoort KN; Drijfhout JW; Huizinga TW; Toes RE; Pruijn GJ
Ann Rheum Dis; 2010 Aug; 69(8):1554-61. PubMed ID: 20448290
[TBL] [Abstract][Full Text] [Related]
11. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
12. Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients.
Harrison P; Pointon JJ; Farrar C; Brown MA; Wordsworth BP
Rheumatology (Oxford); 2006 Aug; 45(8):1009-11. PubMed ID: 16490755
[TBL] [Abstract][Full Text] [Related]
13. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations.
van der Woude D; Lie BA; Lundström E; Balsa A; Feitsma AL; Houwing-Duistermaat JJ; Verduijn W; Nordang GB; Alfredsson L; Klareskog L; Pascual-Salcedo D; Gonzalez-Gay MA; Lopez-Nevot MA; Valero F; Roep BO; Huizinga TW; Kvien TK; Martín J; Padyukov L; de Vries RR; Toes RE
Arthritis Rheum; 2010 May; 62(5):1236-45. PubMed ID: 20131291
[TBL] [Abstract][Full Text] [Related]
14. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
[TBL] [Abstract][Full Text] [Related]
15. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide.
van der Helm-van Mil AH; Verpoort KN; le Cessie S; Huizinga TW; de Vries RR; Toes RE
Arthritis Rheum; 2007 Feb; 56(2):425-32. PubMed ID: 17265477
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population.
Newman WG; Zhang Q; Liu X; Walker E; Ternan H; Owen J; Johnson B; Greer W; Mosher DP; Maksymowych WP; Bykerk VP; Keystone EC; Amos CI; Siminovitch KA
Arthritis Rheum; 2006 Dec; 54(12):3820-7. PubMed ID: 17133579
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
18. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.
van der Woude D; Houwing-Duistermaat JJ; Toes RE; Huizinga TW; Thomson W; Worthington J; van der Helm-van Mil AH; de Vries RR
Arthritis Rheum; 2009 Apr; 60(4):916-23. PubMed ID: 19333951
[TBL] [Abstract][Full Text] [Related]
19. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis.
Szodoray P; Szabó Z; Kapitány A; Gyetvai A; Lakos G; Szántó S; Szücs G; Szekanecz Z
Autoimmun Rev; 2010 Jan; 9(3):140-3. PubMed ID: 19427413
[TBL] [Abstract][Full Text] [Related]
20. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status.
Lee AT; Li W; Liew A; Bombardier C; Weisman M; Massarotti EM; Kent J; Wolfe F; Begovich AB; Gregersen PK
Genes Immun; 2005 Mar; 6(2):129-33. PubMed ID: 15674368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
